Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H. Roboz GJ, et al. Among authors: ravandi f. Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19. Future Oncol. 2016. PMID: 26785287 Free PMC article.
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Ravandi F, et al. Bone Marrow Transplant. 2001 Jun;27(12):1221-5. doi: 10.1038/sj.bmt.1703028. Bone Marrow Transplant. 2001. PMID: 11548839 Clinical Trial.
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. de Lima M, et al. Among authors: ravandi f. Cancer. 2003 Mar 1;97(5):1242-7. doi: 10.1002/cncr.11184. Cancer. 2003. PMID: 12599231 Free article. Clinical Trial.
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Oki Y, et al. Among authors: ravandi f. Blood. 2006 Feb 1;107(3):880-4. doi: 10.1182/blood-2005-06-2450. Epub 2005 Aug 25. Blood. 2006. PMID: 16123215 Free article.
Mature T-cell leukemias.
Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S. Ravandi F, et al. Cancer. 2005 Nov 1;104(9):1808-18. doi: 10.1002/cncr.21405. Cancer. 2005. PMID: 16136598 Free article. Review.
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Giles F, et al. Among authors: ravandi f. Clin Cancer Res. 2005 Nov 1;11(21):7817-24. doi: 10.1158/1078-0432.CCR-05-1070. Clin Cancer Res. 2005. PMID: 16278404 Clinical Trial.
830 results